Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2004 December;45(6) > The journal of Cardiovascular Surgery 2004 December;45(6):569-71

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE JOURNAL OF CARDIOVASCULAR SURGERY

A Journal on Cardiac, Vascular and Thoracic Surgery


Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 2,179


eTOC

 

CASE REPORTS  CARDIAC SECTION


The journal of Cardiovascular Surgery 2004 December;45(6):569-71

Copyright © 2009 EDIZIONI MINERVA MEDICA

language: English

Recombinant factor VIIa use in cardiac surgery - expanding the arsenal therapy for intractable bleeding?

Kogan A. 1, Berman M. 1, Stein M. 2, Vidne B. A. 1, Raanani E. 1

1 Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Campus Petach Tikva, Israel 2 Trauma Unit Rabin Medical Center, Beilinson Campus Petach Tikva, Israel


PDF  


A 72-year-old patient was admitted for mitral valve replacement because of infective endocarditis. Severe intractable bleeding in the early postoperative period was successfully treated with recombinant activated factor VII (rFVIIa). Thereafter, recovery was uneventful, and the patient was discharged on postoperative day 16. The current clinical aspects and experience of rFVIIa use in cardiac surgery are discussed.

top of page

Publication History

Cite this article as

Corresponding author e-mail